Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Incyte Corporation

  Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Incyte
  Corporation

Business Wire

LOS ANGELES -- April 5, 2013

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been
filed in the United States District Court for the District of Delaware on
behalf of a class (the “Class”) comprising all purchasers of the common stock
of Incyte Corporation (“Incyte” or the “Company”) (NASDAQ:INCY) between April
26, 2012 and August 1, 2012 (the “Class Period”). The Complaint alleges that
certain statements issued by Incyte during the Class Period were false and
misleading regarding the Company’s business and financial prospects.

Incyte, a biopharmaceutical company, focuses on the discovery, development and
commercialization of proprietary small molecule drugs for oncology and
treatment of inflammation. The Complaint alleges that Incyte issued misleading
statements concerning demand for the Company’s myelofibrosis drug, Jakafi.

On August 2, 2012, Incyte announced the Company’s second quarter 2012
financial results and disclosed that the sales growth of Jakafi had been much
softer during the second quarter of 2012 than investors and certain stock
analysts had been led to expect. In response to these disclosures, the price
of Incyte stock declined 22% from its August 1, 2012 close of $24.92 per
share, to close at $19.57 per share on August 2, 2012 on heavy trading volume.

No class has yet been certified in this action. Until a class is certified,
you are not represented by counsel unless you retain one. If you purchased
Incyte shares during the Class Period, you have certain rights and have until
May 6, 2013 to move for lead plaintiff status. To be a member of the class you
need not take any action at this time, and you may retain counsel of your
choice. If you wish to learn more or have any questions concerning your rights
or interests with respect to these matters, please contact Michael Goldberg,
Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100,
Los Angeles, California 90067, by telephone at (310) 201-9150, Toll Free at
(888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website
at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.